In many cancer patients who have been treated with immunotherapy, the tumor comes back. New research identifies the cells responsible for thwarting the treatment and offers new insights into how they do it.
Recent research has shown that a drug known as MI-2 can kill cells that cause a fatal brain cancer. But only now have scientists been able to explain how the compound works: by targeting cholesterol production in tumors.
Some cancers have been traced to changes in histones, proteins responsible for packaging DNA and regulating genes. Now, research from Rockefeller scientists shows that, among tumors, mutations to these proteins are a lot more common than previously suspected.
Among other superpowers, stem cells have a knack for fending off viruses like dengue and zika. Scientists have gained new insight into these curious defense strategies—knowledge they say could fuel the development of drugs against a range of diseases.
New research has helped explain what goes wrong in Aicardi-Goutières syndrome, a rare brain disorder. Patients with the disease have genetic abnormalities that may put their cells at risk of accidentally triggering an antiviral response.